CClinicalTrials.gg
TerminatedNCT01257100Updated Jun 4, 2020

Environmental and Genetic Determinants of NPC

An observational study in Nasopharyngeal Neoplasms and Herpesvirus 4, Human, sponsored by National Cancer Institute (NCI). Terminated at 6 sites in Taiwan. Open to participants aged 21 Years to 100 Years. Per ClinicalTrials.gov, last updated 2020-06-04.

Sponsored by National Cancer Institute (NCI) · Observational

Why this study was terminated
Determined not to be Human Subject Research
Study type
Observational
Model
Case-control
Time perspective
Other
Enrollment
3,500
Ages
21 Years to 100 Years
Sex
All
01

Study summary

Background:

  • Nasopharyngeal carcinoma (NPC) a common malignant tumor in southern China and Southeast Asia. Infection with Epstein-Barr virus is believed to be necessary for the development of NPC; non-viral environmental factors, such as dietary consumption of nitrosamines, cigarette smoking, betel nut chewing, wood dust exposure and possibly exposure to formaldehyde, have been implicated in the disease. Genetic susceptibility may also play an important role in the development of NPC. However, more information is needed on the connections between genetic and environmental factors in NPC, particularly in areas where the cancer risk appears to be greatest.

Objectives:

  • To examine the main effects of genetic factors and environmental exposures (e.g., cigarette smoking, betel nut chewing, formaldehyde, wood dust) on nasopharyngeal carcinoma risk.

Eligibility:

  • Cases: Individuals at least 21 years of age who have been diagnosed with NPC at one of the participating hospitals and have been residents of northern Taiwan for at least 6 months.
  • Controls: Hospital patients with diseases other than NPC at least 21 years of age, matched to NPC patients based on hospital, age at diagnosis, gender, and ethnicity.

Design:

  • This study involves a risk factor interview, medical record abstraction and biological sample collection.
  • Participants will respond to interview questions about their lifestyle and risk factors thought to be involved in NPC development.
  • All participants will provide blood and saliva samples for study. Participants who have been diagnosed with NPC will also provide consent to allow researchers to study tissue samples taken during tumor biopsies or surgeries.
  • Treatment will not be provided as part of this protocol.
Read the detailed description

Nasopharyngeal carcinoma (NPC) is one of the most common malignant tumors in southern China and Southeast Asia. While infection with Epstein-Barr Virus (EBV) is believed to be necessary for the development of NPC, non-viral environmental factors have also been implicated in the carcinogenesis of NPC including consumption of salted fish and other nitrosamine containing preserved foods, formaldehyde and wood dust exposure, cigarette smoking, and betel nut chewing. In addition to environmental factors, it is widely accepted that genetic susceptibility plays an important role in the pathogenesis of NPC. Polymorphisms in genes involved in antigen presentation, nitrosamine metabolism and DNA repair have been suggested to be associated with NPC risk, and various chromosomal regions linked to NPC development have been reported. Two recently completed NPC GWAS have reported that the strongest evidence for disease association is observed for SNPs located on the 3.6 Mb Major Histocompatibility Complex (MHC) region on chromosome 6p21 where human leukocyte antigen (HLA) genes are located. These associations highlight the role of both environmental exposures and genomic variation in the etiology of NPC. However, the specific role of EBV on NPC pathogenesis is not completely understood and studies to date have had difficulty pinpointing the specific genetic factors involved in NPC pathogenesis due to the complexity of the MHC region and limited sample size of candidate gene studies.

DCEG investigators and their Taiwan colleagues have a longstanding history of studies to elucidate the role of environmental and genetic factors associated with NPC. A case-control study (375 cases; 327 controls) was conducted in the early 1990s and was followed by a large multiplex family study that was completed in 2006 (358 families; 3,216 individuals). Results from these studies have provided a substantial portion of the epidemiological evidence regarding factors linked to NPC development to date.

At this time, we propose a new case-control study in Taiwan designed to 1) comprehensively evaluate environmental risk factors for NPC; 2) systematically evaluate genetic risk factors for NPC for which previous GWAS and candidate-gene studies have suggested an association; and 3) explore gene-gene and gene-environment interactions for strong main effects identified in our study. In total, up to 2000 cases and 2000 controls are expected to be recruited from five participating hospitals in Northern Taiwan. Cases will consist of 550 incident cases ascertained retrospectively and 1350 incident cases ascertained prospectively. Controls will be hospital based; they will be frequency matched (1:1) to cases on age, gender and ethnicity, and will exclude individuals referred to the participating hospitals due to conditions associated with known NPC risk factors.

This project is a collaborative effort between investigators in Taiwan and at the NCI. Investigators in Taiwan will fund the field recruitment and data collection effort. Results from this study have the potential to further clarify currently controversial environmental risk factors as well as elucidate genetic factors of NPC.

02

Conditions studied

  • Nasopharyngeal Neoplasms
  • Herpesvirus 4, Human

Keywords

  • Nasopharyngeal Carcinoma
  • Epstein-Barr Virus
  • NPC
03

In context

Nasopharyngeal Neoplasms

240 studies on the registry are indexed under Nasopharyngeal Neoplasms; 47 are open to participants now.

This study's enrollment of 3,500 is above the median of 138 across 37 observational studies indexed under Nasopharyngeal Neoplasms.

Browse Nasopharyngeal Neoplasms studies →

Lead sponsor

National Cancer Institute (NCI) is the lead sponsor of 3,506 studies on the registry; 334 are open to participants now.

Of its 402 completed or terminated interventional studies of FDA-regulated products, 365 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This is a hospital based case control population

Eligibility criteria

  • INCLUSION CRITERIA:

Eligibility criteria for cases:

  • Incident diagnosis of NPC between 2010-2015
  • Age greater than or equal to 21 years at NPC diagnosis
  • Histologically confirmed
  • Resident of northern Taiwan greater than or equal to 6 months

Eligibility criteria for controls:

  • Resident of northern Taiwan greater than or equal to 6 months
  • Matched to case based on age at diagnosis, gender, and ethnicity

EXCLUSION CRITERIA:

Exclusion criteria for controls:

  • Clinic attendance due to conditions associated with EBV or smoking
05

Study design

Observational model
Case-control
Time perspective
Other
Enrollment
3,500 participants (actual)

Groups and cohorts

  • Cases with NPC

    Cases with NPC

  • Hospital based controls

    Hospital based controls

06

What researchers measure

Primary outcomes

  1. Nasopharyngeal carcinoma

    NPC diagnosis

07

Study locations

6 sites
  • Koo Foundation Sun Yat-Sen Cancer Center
    Taipei City, Taiwan
  • MacKay Memorial Hospital No 92, Section 2, Zhongshan N. Rd, Zhongshan Dist
    Taipei City, Taiwan
  • Academia Sinica 128 Academia Road
    Taipei, Taiwan
  • Cathay General Hospital 280 Renai Rd, Section 4
    Taipei, Taiwan
  • Far Easter Memorial Hospital 21, NanYa S. Rd, Section 2, Ban-Chiao
    Taipei, Taiwan
  • National Taiwan University Hospital
    Taipei, Taiwan
08

References and documents

Publications

  • Armstrong RW, Imrey PB, Lye MS, Armstrong MJ, Yu MC, Sani S. Nasopharyngeal carcinoma in Malaysian Chinese: salted fish and other dietary exposures. Int J Cancer. 1998 Jul 17;77(2):228-35. doi: 10.1002/(sici)1097-0215(19980717)77:23.0.co;2-7. PubMed 9650558 ↗
  • Bei JX, Li Y, Jia WH, Feng BJ, Zhou G, Chen LZ, Feng QS, Low HQ, Zhang H, He F, Tai ES, Kang T, Liu ET, Liu J, Zeng YX. A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat Genet. 2010 Jul;42(7):599-603. doi: 10.1038/ng.601. Epub 2010 May 30. PubMed 20512145 ↗
  • Blair A, Saracci R, Stewart PA, Hayes RB, Shy C. Epidemiologic evidence on the relationship between formaldehyde exposure and cancer. Scand J Work Environ Health. 1990 Dec;16(6):381-93. doi: 10.5271/sjweh.1767. PubMed 2284588 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01257100
Lead sponsor
National Cancer Institute (NCI)
Collaborators
Academia Sinica, Taiwan, National Taiwan University Hospital, Koo Foundation Sun Yat-Sen Cancer Center, Mackay Memorial Hospital, Far Easter Memorial Hospital, Cathay General Hospital
Responsible party
Sponsor
First posted
Dec 9, 2010
Start date
Dec 8, 2010
Primary completion
Jun 2, 2020
Completion
Jun 2, 2020
Last update
Jun 4, 2020

Study contacts

Allan Hildesheim, Ph.D.
principal investigator · National Cancer Institute (NCI)
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion